Optiscan presented at The Stock Network’s ASX Gems Investment Conference: Healthcare Spotlight, where CEO Dr. Camile Farah outlined the company’s strategic vision and the convergence of its technology, clinical programs, and partnerships during 2025.

In his presentation, Dr. Farah described Optiscan’s role in redefining digital pathology and precision surgery through real-time, slide-free, sub-cellular imaging. He highlighted how Optiscan’s platform technology is designed to move pathology from an analogue, reactive process to a digitally native, point-of-care workflow, enabling live cellular visualisation during surgery rather than days later in the laboratory.

The presentation emphasised 2025 as a pivotal year of validation, with progress across organisational readiness, technology development, clinical studies, and strategic partnerships, all aligned to support regulatory submissions and future commercialisation. Dr. Farah also outlined Optiscan’s vertically and horizontally integrated product suite, spanning surgery, pathology, veterinary medicine, life sciences, oral health, and emerging GI applications.

Dr. Farah shared updates on Optiscan’s expanding software ecosystem, including telepathology live streaming, AI-assisted imaging, and planned integration with robotic surgical systems. He also detailed the company’s multi-year product pipeline and large addressable market opportunities across veterinary, surgical, pathology, robotics, and GI markets, positioning Optiscan at a key inflection point as it progresses toward regulatory milestones and market entry.

Watch the full presentation below: